| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Hong Fang Song last filed a Form 4 in September 2025, as Director at CGON. Hong Fang Song's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Hong Fang Song a below-average insider score of 43/100, based on 4 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -30.2%.
At the last filing, the largest reported position was 2,903,931 shares of CGON. The CGON filings lean toward selling, a net 1,187,298 shares.
Hong Fang Song has 6 Form 4 filings on record from January 2024 to September 2025, all as Director at CG Oncology (CGON), 2024–2025.
The 13 reported transactions were 7 open-market sales, 3 conversions, 2 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $5.0M and 3 sales worth about $45.4M.
The only open-market purchase was 263,157 shares of CGON at an average $19.00 on January 29, 2024, about $5.0M. Twelve months later CGON was down 18%.
The largest open-market sale was 650,455 shares of CGON at an average $35.36 on August 29, 2024, about $23.0M. Twelve months later CGON was down 27%.
1 of the 3 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 2 were not.
Shares as reported in the last Form 4 for each company; the most recent is from September 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | CGON Cg Oncology, Inc. | Director | Sell10b5-1 | 100,000 | $27.80 | $2,779,542.20 | -3.3% | +44.3% | +159.3% | |
| Dec 16, 2024 | CGON Cg Oncology, Inc. | Director | Sell | 700,000 | $28.00 | $19,600,000.00 | -18.9% | -5.3% | +29.6% | |
| Aug 29, 2024 | CGON Cg Oncology, Inc. | Director | Sell | 650,455 | $35.36 | $23,000,088.80 | -14.9% | -7.0% | -26.9% | |
| Jan 29, 2024 | CGON Cg Oncology, Inc. | Director | Buy | 263,157 | $19.00 | $4,999,983.00 | +75.0% | +17.1% | -18.1% |